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Background: Modern combination antiretroviral therapy (cART) has improved survival for people living with HIV
(PLWHIV). Non-AIDS comorbidities have replaced opportunistic infections as leading causes of mortality and
morbidity, and are becoming a key health concern as this population continues to age. The aim of this study is to
estimate the prevalence and incidence of non-AIDS comorbidity among PLWHIV in Denmark in the cART era and
to determine risk factors contributing to the pathogenesis. The study primarily targets cardiovascular, respiratory,
and hepatic non-AIDS comorbidity.
Methods/design: The Copenhagen comorbidity in HIV-infection (COCOMO) study is an observational,
longitudinal cohort study. The study was initiated in 2015 and recruitment is ongoing with the aim of including
1500 PLWHIV from the Copenhagen area. Follow-up examinations after 2 and 10 years are planned. Uninfected
controls are derived from the Copenhagen General Population Study (CGPS), a cohort study including 100,000
uninfected participants from the same geographical region. Physiological and biological measures including
blood pressure, ankle-brachial index, electrocardiogram, spirometry, exhaled nitric oxide, transient elastography
of the liver, computed tomography (CT) angiography of the heart, unenhanced CT of the chest and upper
abdomen, and a number of routine biochemical analysis are uniformly collected in participants from the
COCOMO study and the CGPS. Plasma, serum, buffy coat, peripheral blood mononuclear cells (PBMC), urine,
and stool samples are collected in a biobank for future studies. Data will be updated through periodical linking
to national databases.
Discussion: As life expectancy for PLWHIV improves, it is essential to study long-term impact of HIV and cART.
We anticipate that findings from this cohort study will increase knowledge on non-AIDS comorbidity in PLWHIV
and identify targets for future interventional trials. Recognizing the demographic, clinical and pathophysiological
characteristics of comorbidity in PLWHIV may help inform development of new guidelines and enable us to
move forward to a more personalized HIV care.
Trial registration: ClinicalTrials.gov: NCT02382822.
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The global scale-up of combination antiretroviral ther-
apy (cART) has contributed to a 35% decline in ac-
quired immune deficiency syndrome (AIDS)-related
deaths since 2005 [1], and averted almost 8 million
deaths worldwide [2]. As a consequence, the median
age of people living with HIV (PLWHIV) has steadily
increased and is modelled to be almost 60 years in 2030
[3]. The impact of cART on non-AIDS defining condi-
tions has been less impressive, and prevalence of non-
AIDS comorbidity in PLWHIV is high [3–5]. Multiple
factors may explain the increased burden of non-AIDS
comorbidities, including overrepresentation of trad-
itional risk factors [6], and chronic immune activation
and inflammation [7]. Toxicities associated with the
long-term exposure to cART may also be associated
with non-AIDS comorbidity [8], although early initi-
ation of cART may lower the risk of non-AIDS related
events [9].
The changing disease spectrum will have implications
for clinical HIV care, a prospect that will put new de-
mands on the health care system, and warrants further
studies to assess the burden of disease and risk factors
involved. Primary outcome measures in the Copenhagen
Comorbidity in HIV-infection (COCOMO) study are
characterized with respect to three biological systems,
i.e. cardiovascular, respiratory, and hepatic non-AIDS
comorbidity.
Cardiovascular disease (CVD) has become one of
the leading causes of mortality in PLWHIV [10, 11].
HIV may be an independent risk factor even when
controlling for traditional CVD risk factors [12, 13].
Moreover, CVD-related proportionate mortality may
be rising [14]. Large cohort studies including unin-
fected individuals and multiple CVD endpoints are
warranted to ascertain further insight into the risk
factors and mechanisms driving CVD in PLWHIV in
the current cART era.
Respiratory non-AIDS comorbidity in PLWHIV has
received less attention. Smaller clinic-based cross-
sectional studies using pulmonary function testing
have been conducted [15, 16]. Few studies have also
assessed pulmonary function longitudinally [17–20].
Data from these studies indicate an increased risk of
non-AIDS respiratory comorbidity in PLWHIV. Thus,
PLWHIV may be more susceptible to the harms of
smoking than the general population, but the mech-
anistic factors behind the proposed increased risk of
respiratory comorbidity have not been thoroughly
investigated.
Liver related deaths in PLWHIV are often related to
hepatitis C virus (HCV) or hepatitis B virus (HBV),
but may also occur in the absence of chronic viral
hepatitis [21]. This may be due to the presence ofmultiple risk factors including high alcohol consump-
tion, metabolic disorders driven by HIV, viral replica-
tion, and use of cART [22–25]. Studies have also
shown that non-alcoholic fatty liver disease (NAFLD)
and fibrosis is associated with duration of HIV, persist-
ent HIV viral replication, cART use, as well as genetic
variants [26–29]. As with CVD and respiratory comor-
bidity, these results suggest contributory effects of
HIV-related factors.Study objectives
The overall objective of the COCOMO study is to assess
the burden of non-AIDS comorbidity in PLWHIV, and
to gain further insight into the aetiology of non-AIDS
comorbidity. We wish to identify both HIV-related and
HIV un-related risk factors involved in the pathogenesis
of non-AIDS comorbidity.
AIM 1: To determine if prevalence and incidence of
cardiovascular, respiratory, and hepatic diseases in
HIV-infected persons are different from what is
found in demographically similar uninfected persons
when both groups have uniformly measured clinical
data and information regarding risk factors. Clinically
measured primary outcomes include 1) non-calcified
plaques detected by cardiac CT angiography, 2) dynamic
lung function indices measured by spirometry, and
3) liver fibrosis measured by transient elastography
(TE). Several other outcome measures are included
(Table 1).
AIM 2: To identify HIV-related and HIV-unrelated
risk factors that contribute to the pathogenesis of
cardiovascular, respiratory, and hepatic diseases in
HIV-infected persons and to study the interaction
between these.
Hypotheses are registered at clinicaltrials.gov
(NCT02382822).Methods/design
Study design
The COCOMO study is a non-interventional, obser-
vational, longitudinal study initiated in March 2015.
The study aims to enroll up to 1500 PLWHIV from
two sites in Copenhagen (Rigshospitalet, University
of Copenhagen, and Hvidovre Hospital, University of
Copenhagen). Uninfected controls will be derived
from the Copenhagen General Population Study
(CGPS) with a study population of more than
100,000 participants from the greater Copenhagen
area [30, 31]. An overview of physical measurement
and collection of biomaterial (Table 1), hematological
Table 1 Clinical measurements and collection of biomaterial
Measurements Description
Anthropometry Height: Stadiometer (Soehnle, Nassau,
Germany) without shoesa
Weight: Scale (Soehnle, Nassau, Germany)
without shoes or heavy clothinga
Waist and hip circumference: Measuring tape
(SECA, Birmingham, UK)a
Ankle-brachial index Doppler (Sonotrax Basic A, Edan, San Diego,
CA, U.S.)a
Blood pressure IntelliVue MP5SC (Philips, Amsterdam,
Netherlands)a
Electrocardiogram Cardiosoft V6.73 (GE Healthcare,
Buckinghamshire, UK)a
Spirometry EasyOne® ultrasonic spirometer (ndd Medical,
Zürich, Switzerland)a
eNO NIOX VERO® (Aerocrine AB, Solna, Sweden)c
Transient elastography Fibroscan (Fibroscan 402, EchosensTM, Paris,
France)a
CT scans CT angiography, CACS, CT chest, CT upper
abdomen (Aquillion One scanner, Toshiba
Medical Systems, Otawara-shi, Tochigi-ken,
Japan)a
Blood (non-fasting) Peripheral venous blood: Buffy coata, PBMCb,
plasmaa, seruma
Urine (spot, non-fasting) Collected in sterile polypropylene tube
(Sarstedt, Nürnbrecht, Germany)c
Stool (non-fasting) Collected in polypropylene tube (Sarstedt,
Nürnbrecht, Germany)c
aCollected uniformly in the Copenhagen Co-morbidity in HIV infection
(COCOMO) Study cohort and in the Copenhagen general population study
(CGPS). bCollected in the COCOMO study cohort only. cCollected uniformly in a
subsample of the COCOMO cohort and in the CGPS, see text
Abbreviations: CACS coronary artery calcium score, CT computed tomography,
eNO exhaled nitric oxide and PBMC peripheral blood mononuclear cells. See
Methods for further details
Table 2 Hematological and biochemical measures
Measurements Description
Hematology Hemoglobin, hematocrit, leucocytes, differential
count, thrombocytes, red cell dimensions
Electrolytes and iron
metabolism
Sodium, potassium, calcium, iron, magnesium,
ferritin, transferrin
Liver/ organ related Aspartate aminotransferase, alanine
aminotransferase, alkaline phosphatase, bilirubin,
gamma glutamyltransferase, albumin, antitrypsin,
amylase, creatinine kinase, lactate dehydrogenase
Coagulation Activated partial thromboplastin time, coagulation
factor II+ VII+ X, D-dimer, fibrinogen
Lipids Total cholesterol, remnant cholesterol, HDL-
cholesterol, LDL-cholesterol, triglycerides,
adiponectin, lipoprotein, apolipoprotein A, B, and E
Metabolic Glucose, HbA1c, ethanol
Renal function Creatinine, urea, uric acid
Thyroid function Thyroid stimulating hormone, free T3/T4
Immunology Immunoglobulin A and E, rheumatoid factor IgM,
complement C3
Inflammation High sensitivity C-reactive protein
All measures are analyzed uniformly in the Copenhagen co-morbidity
(COCOMO) study cohort and in the Copenhagen general population study
(CGPS) at Biochemical Department, University Hospital Herlev, Copenhagen
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questionnaire are given (Table 3).
Follow up examinations
Each participant in the COCOMO study and CGPS will
be evaluated at baseline and repeat evaluations will be
performed after 10 years for all clinically measured out-
comes, except CT scans in the CGPS. For a detailed de-
scription of follow up analysis see Fig. 1. In addition,
follow up examinations in the COCOMO study, and in
a subsample of the CGPS (n = 500), will be performed
after 2 years and include pulmonary function testing and
transient elastography (TE).
Participants
Eligibility criteria
To be eligible for the COCOMO, study participants
must be a minimum age of 18 years, infected with HIV-
1, out-patient at either Department of Infectious Dis-
eases at University Hospital Copenhagen or HvidovreUniversity Hospital, and be able to sufficiently under-
stand oral and written study information in Danish or
English to provide an informed consent. Insufficient
knowledge of the Danish language does not exclude
individuals if questionnaires can be filled out by the
help of relatives or staff. Contraindications to the
various measures performed in the study (i.e. renal
impairment or contraindications to beta blocking
agents used for CT angiography) do not exclude a
participant from other parts of the study. In total,
4500 PLWHIV are eligible for inclusion. This number
comprises ~95% of PLWHIV in Eastern Denmark/
Zealand (inhabited by approximately 2,5 mill people).
To be eligible for participation in the CGPS, individ-
uals must be a minimum of 20 years of age and res-
ide in the greater Copenhagen area. Starting from
2014 a large number of the first 100,000 participants
from the CGPS were re-invited by regular mail. Of all
inhabitants in the selected area, 25% of the 20–
40 years old and 100% of the >40 years old are in-
vited. A random sample of approximately 10,000 indi-
viduals above 40 years of age will have an
unenhanced coronary artery calcium score (CACS)
and CT angiography of the heart, and approximately
2000 will, in addition, have a CT scan of the chest
and upper abdomen as described under methods.
Scanning protocols in the COCOMO and CGPS stud-
ies are identical.
Table 3 Overview of variables recorded by questionnaires
Variable Examples
External risk factors
Smoking Current, previous, and passive smoking,
cumulative pack-years, type, filters, e-cigarettes
Alcohol/drug abuse Current and previous alcohol intake, intravenous
drug use, cannabis, methadone treatment
Biomass fuel/
environmental
exposure
Occupational dusts, organic, inorganic gasses,
vapors, and fumes (outdoor and indoor)
Demographics Ethnicity, nationality, marital status, children
Education/income Level of education, house-hold income
Work Employment, income, night work
Diet Meat intake, vegetable intake
Daily living Physical activity, social support, sleeping,
stress, sun exposure
Medication use Prescription and doses
Internal risk factors
Gender and ethnicity Ethnicity, place of birth
Perinatal/childhood
events
Birthweight, delivery at term, breast feeding,
respiratory tract infections
Family history of
disease
AMI, apoplexy, asthma, COPD, hypertension,
diabetes, cancer, depression
Questions for females Pregnancies, menarche- and menopause age,
abortions
Self-reported disease Asthma, COPD, allergy, diabetes
Symptoms Angina, dyspnea (MRC), cough, wheeze, sputum,
reflux
Risk factors for non-AIDS comorbidity, self-reported disease, and subjective
morbidity are assessed. Under each variable a non-exhaustive list of examples
are given
Abbreviations: AMI acute myocardial infarction, COPD chronic obstructive
pulmonary disease and MRC medical research council dyspnea scale
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The study includes several end-points, and the necessary
sample size varies accordingly. One of the calculations
used to estimate the required sample-size is based on
forced expiratory volume in one-second (FEV1) decline,
because there is existing solid longitudinal data on this
endpoint, and because there is a natural age associated
decline of FEV1. Sample size was estimated aiming to
find a difference in the rate of forced expiratory volume
in one-second (FEV1) decline per year between PLWHIV
vs. uninfected controls. The standard deviation (SD) of
FEV1 decline was derived from large general population
studies and estimated to be SD = 60 mL/year [32, 33]. A
difference (Δ) of 8 mL/year in HIV-infected vs. unin-
fected, allocation ratio of 1:4 (HIV-infected: uninfected),
power = 0.9, and alpha level = 0.05, would require ap-
proximately 750 PLWHIV and 3000 controls. A clinically
more relevant decline would require a smaller sample,
e.g. Δ: 10 mL/year would require approximately 500PLWHIV under the same conditions. A power graph for
various Δs and powers can be found in Additional file 1
along with power calculations for other outcomes. Esti-
mations were conducted using G*Power 3.1 and R 3.2.0
[34, 35].
Planned statistical analysis
Prevalence and risk factors for non-AIDS comorbidity
will be calculated based on baseline data. For some out-
come data we plan to match PLWHIV with uninfected
control 1:5 on age and gender. Student’s t-test, Mann-
Whitney U-test and Pearson’s chi-squared test and ap-
propriate uni- and multivariate regression analyses will
be used at baseline. For prospective studies, Cox regres-
sion, Kaplan-Meier curves, log-rank test, and mixed ef-
fects models will be used. In general, missing data is
expected to be low and multiple imputations not likely
to be required. Characteristics for loss-to follow up will
be assessed.
Ethical considerations
All participants provide oral and written informed
consent before study inclusion. The COCOMO study
(H-8-2014-0004) and CGPS study (H-KF-01-144/01)
have obtained approval from the Ethics Committee
of the Capital Region and from the Danish Data Pro-
tection Agency. Although the study is not intended
to be a screening project, participants are subjected
to physical exams, laboratory tests, and imaging pro-
cedures. Screening is an area of controversy, may
carry risks, and introduce false-positive and false-
negative test results. Thus, each participant can
choose to give consent to be contacted upon encoun-
ter of abnormal test results (e.g. anaemia, hyperten-
sion, renal impairment, pulmonary nodules, liver
fibrosis). In such cases, participants will be referred
for relevant follow up. All participants give a specific
consent to storing of biological samples for future
studies. The CT scan exposes participants to a radi-
ation dose of five to a maximum of eight millisie-
verts (mSv). Although low, this radiation dose may
cause an increase in lifetime risk of radiation-
induced cancer. Before giving consent to the CT
scan, participants have received both written and oral
information about the radiation exposure and cancer
risk. All adverse events and abnormal test results in
the study are recorded.
Physical measurements and collection of biomaterial in
the COCOMO and CGPS study
The COCOMO and CGPS study collects all data uni-
formly. Blood pressure is measured twice electronically
on right and left arm, respectively, with the participant
in a relaxed seated position using IntelliVue MP5SC
Fig. 1 A timeline of the data collection in the Copenhagen Comorbidity in HIV (COCOMO) Study and the Copenhagen General Population Study
(GCPS). # Collected in the COCOMO study cohort only. *Collected in a subsample of the cohort. ‡ Collected in a subsample of the CGPS cohort.
Abbreviations: CACS (coronary artery calcium score), CT (computed tomography), eNO (exhaled nitric oxide), and PBMC (peripheral blood mononuclear
cells). See Methods for further details
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(ECG) is measured with a 12-lead ECG (Cardiosoft
V6.73 GE Healthcare, Buckinghamshire, UK). Ankle-
brachial-index (ABI) is measured in supine position in
both extremities using a Doppler meter (Sonotrax
Basic A 294534, Edan, San Diego, CA, US) by deter-
mining the systolic pressure of posterior tibial artery.
Alternatively, the pressure of dorsalis pedis is deter-
mined. Pulse and peripheral arterial saturation is mea-
sured by fingertip puls-oximetry using IntelliVue
MP5SC (Philips).
Spirometry is performed using the EasyOne® ultra-
sonic spirometer (ndd Medical, Zürich, Switzerland)
with ndd spirettes (ndd Medical) in accordance with
American Thoracic Society/European Respiratory So-
ciety guidelines [36], except that participants arestanding in upright position without the use of a
nose clip. The spirometer has an inbuilt calibration
function that is checked regularly using a standard-
ized 3-L syringe to confirm volume measurement to
within ± 3% accuracy. In participants with a ratio be-
tween FEV1 and forced vital capacity (FEV1/FVC)
less than 0.7, a repeat spirometry is conducted
15 min after bronchodilation with 400 μg salbutamol
given by inhalation (Ventoline® Diskus, Glaxo Smith
Kline, Middlesex, UK). In a subset of COCOMO par-
ticipants (N = 425) and in the CGPS nitric oxide is mea-
sured in exhaled breath (eNO) using NIOX VERO®
(Aerocrine AB, Solna, Sweden) [37].
Transient elastography (TE) (Fibroscan 402, Echo-
sens™, Paris, France) is used to quantify the liver stiff-
ness (LS) with the participant in supine position. A
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teria: At least 10 valid measurements, a success rate
above 60% and an interquartile range (IQR) less than
30% of the median LS [38]. The scanner is calibrated
regularly by the manufacturer.
Collection of biomaterial in the COCOMO study only
Venous blood is collected non-fasting. The following
blood components are collected and stored a) whole
blood (ethylenediamine tetraacetic acid [EDTA]-anti-
coagulated), b) buffycoat (EDTA-anti-coagulated), c)
plasma (EDTA-anti-coagulated), and d) serum (Z Serum
Sep Clot Activator). Venous blood for plasma samples is
stored on ice until centrifugation in a cold-centrifuge at
4 °C. Buffycoats are transferred to 1 ml MAT-3741 2D
screw tubes (Fisher Scientific, Hampton, NH, U.S.) and
for RNA-tubes 10% DMSO is added.
Peripheral blood mononuclear cells (PBMCs) from
all COCOMO participants are isolated (lithium-hepa-
rinized anti-coagulated), and cryopreserved within
one hour of venipuncture. Leucosep® (Greiner Bio-
One, Kremsmuenster, Austria) is used as separation
media [39], and a freezing media of RPMI-1640, fetal
bovine serum (FBS), and 10% DMSO [40] is used.
Cells are frozen using a stepwise temperature de-
crease to −80 °C using CoolCell® (BioCision, Lark-
spur, CA, U.S.) [39]. Cryovials are transferred to
liquid nitrogen within 72 h. A detailed protocol can
be found elsewhere [41]. Approximately half of the
COCOMO cohort is invited to provide a urine and/
or stool sample. Non-fasting spot-urine samples are col-
lected in a sterile polypropylene tube (Sarstedt,
60.549.001, Nürnbrecht, Germany) and stored at −80 °C
within 4 h of sampling. Stool is collected by participants
in a polypropylene tube with DNA stabilizer reagent (Stra-
tec Molecular Gmbh, 1038111200, Berlin, Germany) and
stored at −80 °C within three days of collection. In a
smaller subset (N = 160) mouth wash has been collected
by gargling of 10 mL saline (9 mg/mL) for one minute
and stored at −80 °C.
Computed tomography (CT) scans
The complete CT scan protocol includes a number of
scans performed in the following sequence: Unen-
hanced CACS, scan of the upper abdomen, abdominal
single slice acquisition for measurements of visceral
adipose tissue, and low-dose chest CT. Finally, a con-
trast enhanced coronary angiography is performed
with iodixanol (Visipaque®, GE Healthcare, Brøndby
Denmark). If resting pulse exceeds 55 beats per minute
(bpm), participants will be prepared for the coronary
angiography with an orally administered β1-receptor
blocker (Metocar, STADA Nordic, Herlev, Denmark).
A maximum dose of 150 mg based on systolic bloodpressure, weight, and pulse may be administered. Par-
ticipants with moderate to severe COPD/asthma will
receive Ivabradin 15 mg (Procoralan, Servier, Freder-
iksberg, Denmark) instead of a β1-receptor blocker.
Only participants with a pulse below 70 bpm receive
CT-angiography with intravenous contrast. Immedi-
ately before CT angiography is performed, one dose of
0.4 mg oral spray nitroglycerin (Nitrolingual, Pohl Bos-
kamp, Hohenlockstedt, Germany) is administered.
Contraindications to nitroglycerin include measured
blood pressure less than 110 mmHg and concomitant
treatment with other phosphodiesterase inhibitors.
The maximum allowed radiation dose for the complete
sequence is 8 mSv. Chest CT will not be performed in
obese participants, where the expected radiation dose
is higher than 8 mSv. All scans are performed on an
Aquillion One scanner (Toshiba Medical Systems,
Otawara-shi, Tochigi-ken, Japan). Scan parameters are
described in Additional file 2.
Questionnaires
All study participants complete a general health re-
lated paper questionnaire in Danish comprising more
than one hundred items and a specific respiratory
questionnaire. In the COCOMO study a specific ques-
tionnaire regarding current medication and illicit drug
use is used. All items comprise questions on internal
and external risk factors for development of non-AIDS
comorbidities and information on self-reported symp-
toms and diseases. An overview of the variables used
in the questionnaires is given in Table 3. Staff reviews
completed questionnaires with each study participant
for validation purpose. Questionnaires from the
COCOMO and CGPS studies are scanned to automat-
ically retrieve data.
Other data sources
For the COCOMO study HIV-related variables will be
retrieved from patient records. Information on vital
status, medicine use and discharge diagnoses will be
retrieved from the National Danish registries. The
Civil Registration System (CRS) provides each resident
of Denmark with a unique personal identifier and is
updated daily with changes in vital status including
date of emigration and date of death [42]. The Danish
National Patient Register (NPR) contains information
on all admissions to Danish Hospitals including dis-
charge diagnosis according to the International Classi-
fication of Disease (ICD)–10 from 1994 [43]. The
Registry of Medicinal Product Statistics contains all
information on medicines since 1994, including all
prescription and non-prescription drug sales from
pharmacies and shops, and all deliveries from the
general practitioners and hospitals [44].
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Non-AIDS comorbidities are frequently encountered
in the routine care of PLWHIV. As the number of
PLWHIV has increased, and this population continues
to age, information on the burden of comorbidity and
potential risk factors leading to disease is warranted.
The current study is an observational and longitu-
dinal cohort study. It includes several clinical mea-
sures and is conducted in parallel to a large control
cohort (CGPS) from the same geographical area using
uniformly collected data. The primary goal is to iden-
tify the burden and the determinants of non-AIDS
comorbidity. Primary outcome measures are charac-
terized with respect to three biological systems, i.e.
cardiovascular, respiratory, and hepatic non-AIDS co-
morbidity. Beyond the primary research questions,
this study will establish a biobank for future prospect-
ive studies to assess pathogenesis of comorbidity in
HIV infection.
Despite numerous studies on non-AIDS comorbid-
ity, many questions remain: What is the burden of
disease in the current cART era and which mecha-
nisms are at play? What is the optimal clinical care,
screening, and monitoring of patients with comorbidi-
ties? How does socioeconomic status affect develop-
ment and prognosis on comorbidity? How will cART
be tolerated in the elderly and what are the effects of
polypharmacy in the elderly? In 2030, 28% of
PLWHIV are expected to have three comorbidities or
more, and 54% will be prescribed co-medication [3].
Most randomized trials of cART have, however, ex-
cluded elderly PLWHIV or those with comorbidities,
and there is a continuous need to track non-AIDS
comorbidity in non-interventional studies.
This study has a priori been designed to assess
non-AIDS comorbidities. Thus, one of the main
strengths is the multimodal assessment of risk factors
associated with non-AIDS comorbidity. This will also
be one of the largest cohort studies with assessment
of non-AIDS comorbidity using clinical measured
endpoints. Other cohort studies that are ongoing with
use of various clinical examinations, include the Mul-
ticenter AIDS cohort study (MACS) [45], Women’s
interagency HIV study (WIHS) [46], the AIDS linked
to intravenous experience (ALIVE) study [47], all
from the United States, the cohort from a HIV meta-
bolic clinic in Italy [4], and most recently the AGE-
HIV cohort study from the Netherlands [48]. Besides
the use of a control cohort with uniformly collected
data, a main strength also includes the use of Danish
registry data. These registries will allow linkage of
data from the COCOMO study cohort to complete
information on cause and date of death, hospital dis-
charge, and of prescription medicine.A weakness includes selection bias such as healthy
volunteer bias, as those with serious illness or disability
may be less likely to participate. Non-participation may
include individuals that have difficulty attending on-site
examinations (e.g. IDUs, elderly, home- or nursing
home-bound). CGPS participants are recruited at ran-
dom whereas COCOMO participants are recruited at
their regular ambulatory visits. Exact reasons for non-
participation will not be registered. However, the number
of non-participaters will be registered, and to some extent,
it will be possible to compare the non-participators with
the participators, e.g. in respect to age, gender, CD4
count, and viral load. All PLWHIV registered as out-
patients at the two sites receive an invitation to partici-
pate. Advertisement is found at the Patient Organization
HIV Denmark (www.hiv-danmark.dk) and as posters at
the two sites.
As the study collects information on some early life
events through self-reports (i.e. exposure to passive smok-
ing, childhood respiratory infections), a recall-bias cannot
be precluded. However, few non-AIDS comorbidity stud-
ies have previously collected such information. Although
the study is large, a sample size of 1500 PLWH precludes
the study from examining rare clinical diagnoses such as
specific non-AIDS cancers. A loss to follow up is antici-
pated for the clinically measured endpoints, and has been
taken into account in power analysis. Finally, the study is
confined to a restricted geographic area with individuals
of primarily Western European descent, and although
broad eligibility criteria are used, results may not be
generalizable to other parts of the world.
In conclusion, the spectrum of disease in PLWHIV
has changed and non-AIDS comorbidity will be more
common as this population continues to age. This will
have implications for the clinical care and continue to
put new demands on health authorities. This study has
the potential to identify novel risk factors for comor-
bidity in PLWHIV that may be used to guide future
interventional studies. Guidelines on screening and
monitoring of non-AIDS comorbidity continue to
evolve and may help to reduce the burden of non-AIDS
comorbidity. Use of data will be confined to the study
group, but potential collaborators or request for data
can be submitted at cocomo.rigshospitalet@regionh.dk.
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